These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6244139)

  • 1. Experimental prevention of venous thrombosis.
    Hladovec J; Prerovský I
    Czech Med; 1980; 3(1):11-9. PubMed ID: 6244139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the antithrombotic activity of "antiplatelet" drugs based on protection of endothelium?
    Hladovec J
    Thromb Haemost; 1979 Jun; 41(4):474-8. PubMed ID: 483235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Critical evaluation of the usefulness of drugs inhibiting platelet function in the prevention of postoperative deep venous thrombosis and in ischemic cardiopathy].
    Verstraete M
    Recenti Prog Med; 1980 Apr; 68(4):361-81. PubMed ID: 6992244
    [No Abstract]   [Full Text] [Related]  

  • 4. Antithrombotics in view of thrombosis models.
    Hladovec J
    Thromb Res; 1986 Sep; 43(5):545-61. PubMed ID: 2944244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
    Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of platelet function in the prevention of arterial thrombosis.
    Harker LA
    Ser Haematol; 1975; 8(3):105-24. PubMed ID: 790583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Platelet anti-aggregant drugs and ischemic cardiopathy: evaluation of the effect on platelet aggregation and on antithrombin III].
    Avellone G; Mandalà V; Novo S; Pinto A; Riolo FP; Davì G; Raneli G
    Boll Soc Ital Cardiol; 1981; 26(8):697-712. PubMed ID: 6289854
    [No Abstract]   [Full Text] [Related]  

  • 8. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
    Farias WR; Nazareth RA; Mourão PA
    Thromb Haemost; 2001 Dec; 86(6):1540-6. PubMed ID: 11776325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement.
    Francis CW; Pellegrini VD; Leibert KM; Totterman S; Azodo MV; Harris CM; Cox C; Marder VJ
    Thromb Haemost; 1996 May; 75(5):706-11. PubMed ID: 8725709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of thromboembolism with antiaggregants (author's transl)].
    Zekert F
    Langenbecks Arch Chir; 1977 Nov; 345():359-64. PubMed ID: 592989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of calcium antagonists on endothelium.
    Hladovec J
    Arzneimittelforschung; 1979; 29(8):1101-3. PubMed ID: 583006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).
    Xiong J; Fang W; Fang W; Bai L; Huo J; Kong Y; Yunman L
    J Pharm Pharmacol; 2009 Jan; 61(1):89-94. PubMed ID: 19126301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Warfarin in the treatment of antiphospholipid syndrome].
    Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
    Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacology of anti-platelet agents].
    Lecompte T; Kher A; Gaillard JL; Samama M
    J Mal Vasc; 1983; 8(1):3-16. PubMed ID: 6302191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of combined use of anticoagulants and antiplatelet agents in the early stage after prosthetic valve replacement].
    Toyohira H; Nakamura K; Kariyazono H; Yamada K; Moriyama Y; Shimokawa S; Saigenji H; Taira A
    Kyobu Geka; 1995 Aug; 48(9):749-55. PubMed ID: 7564036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
    Fonseca RJ; Oliveira SN; Melo FR; Pereira MG; Benevides NM; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):539-45. PubMed ID: 18327402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current clinical results of antiplatelet medication].
    Ordinas A
    Sangre (Barc); 1984; 29(4-C):833-40. PubMed ID: 6393391
    [No Abstract]   [Full Text] [Related]  

  • 20. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.